125 related articles for article (PubMed ID: 34263700)
1. Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab.
Vuolteenaho K; Tuure L; Nieminen R; Laasonen L; Leirisalo-Repo M; Moilanen E;
Scand J Rheumatol; 2022 May; 51(3):180-185. PubMed ID: 34263700
[TBL] [Abstract][Full Text] [Related]
2. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
[TBL] [Abstract][Full Text] [Related]
3. Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.
Rantalaiho V; Sandström T; Koski J; Hannonen P; Möttönen T; Kaipiainen-Seppänen O; Yli-Kerttula T; Kauppi MJ; Uutela T; Malmi T; Julkunen H; Laasonen L; Kautiainen H; Leirisalo-Repo M;
Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1450-1458. PubMed ID: 30295425
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Leirisalo-Repo M; Kautiainen H; Laasonen L; Korpela M; Kauppi MJ; Kaipiainen-Seppänen O; Luosujärvi R; Luukkainen R; Karjalainen A; Blåfield H; Uutela T; Ilva K; Julkunen HA; Paimela L; Puolakka K; Moilanen E; Hannonen PJ; Möttönen T;
Ann Rheum Dis; 2013 Jun; 72(6):851-7. PubMed ID: 22753402
[TBL] [Abstract][Full Text] [Related]
5. Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.
Levitsky A; Wick MC; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; van Vollenhoven RF; Rantalaiho V
Clin Exp Rheumatol; 2016; 34(6):1065-1071. PubMed ID: 27607411
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.
Väänänen T; Vuolteenaho K; Kautiainen H; Nieminen R; Möttönen T; Hannonen P; Korpela M; Kauppi MJ; Laiho K; Kaipiainen-Seppänen O; Luosujärvi R; Uusitalo T; Uutela T; Leirisalo-Repo M; Moilanen E;
PLoS One; 2017; 12(8):e0183294. PubMed ID: 28841649
[TBL] [Abstract][Full Text] [Related]
7. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Rantalaiho V; Korpela M; Laasonen L; Kautiainen H; Järvenpää S; Hannonen P; Leirisalo-Repo M; Blåfield H; Puolakka K; Karjalainen A; Möttönen T;
Arthritis Res Ther; 2010; 12(3):R122. PubMed ID: 20576092
[TBL] [Abstract][Full Text] [Related]
8. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
9. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
Rantalaiho V; Kautiainen H; Järvenpää S; Korpela M; Malmi T; Hannonen P; Kaipiainen-Seppänen O; Yli-Kerttula T; Möttönen T; Mustila A; Karjalainen A; Paimela L; Uutela T; Leirisalo-Repo M;
J Rheumatol; 2014 Dec; 41(12):2379-85. PubMed ID: 25274892
[TBL] [Abstract][Full Text] [Related]
10. Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.
Sandström T; Rantalaiho V; Yli-Kerttula T; Kautiainen H; Malmi T; Karjalainen A; Uusitalo T; Julkunen H; Kaipiainen-Seppänen O; Paimela L; Puolakka K; Uutela T; Möttönen T; Hannonen P; Leirisalo-Repo M; Laasonen L; Kauppi M;
J Rheumatol; 2020 Aug; 47(8):1160-1164. PubMed ID: 31732558
[TBL] [Abstract][Full Text] [Related]
11. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Kuusalo L; Puolakka K; Kautiainen H; Blåfield H; Eklund KK; Ilva K; Kaipiainen-Seppänen O; Karjalainen A; Korpela M; Valleala H; Leirisalo-Repo M; Rantalaiho V;
Scand J Rheumatol; 2015; 44(6):449-55. PubMed ID: 26324784
[TBL] [Abstract][Full Text] [Related]
12. Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.
Güler-Yüksel M; Allaart CF; Watt I; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Schaardenburg D; van Krugten MV; Dijkmans BA; Huizinga TW; Lems WF; Kloppenburg M
Osteoarthritis Cartilage; 2010 Oct; 18(10):1256-62. PubMed ID: 20691795
[TBL] [Abstract][Full Text] [Related]
13. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Hambardzumyan K; Bolce R; Saevarsdottir S; Cruickshank SE; Sasso EH; Chernoff D; Forslind K; Petersson IF; Geborek P; van Vollenhoven RF
Ann Rheum Dis; 2015 Jun; 74(6):1102-9. PubMed ID: 24812287
[TBL] [Abstract][Full Text] [Related]
15. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J;
Lancet; 2012 May; 379(9827):1712-20. PubMed ID: 22464340
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
Rantalaiho V; Puolakka K; Korpela M; Hannonen P; Möttönen T
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
[TBL] [Abstract][Full Text] [Related]
17. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.
Ornbjerg LM; Ostergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Ringsdal VS; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Dencker D; Hansen A; Andersen AR; Hetland ML
Ann Rheum Dis; 2013 Jan; 72(1):57-63. PubMed ID: 22532636
[TBL] [Abstract][Full Text] [Related]
18. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
19. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
[TBL] [Abstract][Full Text] [Related]
20. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
